Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis

Cancer

Volumn 97, Issue 12, 2003, Pages 3053-3060

  Cole, Bernard F ^a   Glantz, Michael J ^b   Jaeckle, Kurt A ^c   Chamberlain, Marc C ^d   Mackowiak, John I ^e  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Center for Outcomes Research   (United States)

Author keywords

Cerebrospinal fluid; Neoplastic meningitis; Quality of life; Quality adjusted time without symptoms or toxicity; Randomized controlled trial

Indexed keywords

CYTARABINE; METHOTREXATE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL DECISION MAKING; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLID TUMOR; SOLID TUMOR NEOPLASTIC MENINGITIS; SUSTAINED RELEASE PREPARATION;

ADULT; CYTARABINE; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; HUMANS; INJECTIONS, SPINAL; MENINGEAL NEOPLASMS; MENINGITIS; METHOTREXATE; NEOPLASMS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 0038390612     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11449     Document Type: Article

References (21)

1. Bleyer WA. Leptomeningeal cancer in leukemia and solid tumors. Curr Probl Cancer. 1988;12:184-238.
2. Chamberlain MC. Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol. 1998;37:271-284.
3. Gonzalez-Vitale JC, Garcia-Bunuel R. Meningeal carcinomatosis. Cancer. 1976;37:2906-2911.
4. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt™) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5:3394-3402.
5. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
6. Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol. 1997;15:330-340.
7. Gelber RD, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol. 1986;4:1772-1779.
8. Goldhirsch A, Gelber RD, Simes RJ, et al. Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis. J Clin Oncol. 1989;7:36-44.
9. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med. 1990;9:1259-1276.
10. Gelber RD, Cole BF, Gelber S, et al. Comparing treatments using quality-adjusted survival: the Q-TWiST method. Am Stat. 1995;49:161-169.
11. Gelber RD, Goldhirsch A, Cavalli F. Quality-of-life-adjusted evaluation of a randomized trial comparing adjuvant therapies for operable breast cancer. Ann Intern Med. 1991;114: 621-628.
12. Gelber RD, Goldhirsch A, Hürny C, et al. Quality of life in clinical trials of adjuvant therapies. J Natl Cancer Inst Monogr. 1992;11:127-135.
13. Cole BF, Gelber RD, Goldhirsch A. A quality adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. Stat Med. 1995;14:1771-1784.
14. Gelber RD, Cole BF, Goldhirsch A, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: a meta-analysis using quality-adjusted survival. Lancet. 1996;347:1066-1071.
15. Gelber RD, Lenderking WR, Cotton DJ, et al. Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. Ann Intern Med. 1992;116:961-966.
16. Lenderking WR, Gelber RD, Cotton DJ, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med. 1994;330:738-743.
17. Gelber RD, Goldhirsch A, Cole BF, et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst. 1996;88:1039-1045.
18. Cole BF, Gelber RD, Kirkwood JM, et al. A quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment for high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study (E1684). J Clin Oncol. 1996;14:2666-2673.
19. Cole BF, Solal-Céligny P, Gelber RD, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol. 1998;16:2339-2344.
20. Zee B, Cole BF, Li T, et al. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol. 1998;16:2834-2839.
21. Kilbridge KL, Cole BF, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2B for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002;20:1311-1318.